Mereo BioPharma Group PLC (MREO)
3.82
-0.23
(-5.68%)
USD |
NASDAQ |
Nov 14, 16:00
3.835
+0.02
(+0.39%)
After-Hours: 20:00
Mereo BioPharma Group Research and Development Expense (Quarterly): 4.946M for June 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 4.946M |
| March 31, 2024 | 3.994M |
| Date | Value |
|---|---|
| June 30, 2023 | 3.712M |
| March 31, 2023 | 5.307M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
3.712M
Minimum
Jun 2023
5.307M
Maximum
Mar 2023
4.490M
Average
4.47M
Median
Research and Development Expense (Quarterly) Benchmarks
| NuCana PLC | 8.540M |
| TC BioPharm (Holdings) PLC | 1.648M |
| Adaptimmune Therapeutics PLC | 40.45M |
| Biodexa Pharmaceuticals PLC | -- |
| Autolus Therapeutics PLC | 36.61M |